Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8420676 | CUBIST PHARMS LLC | Oxazolidinone derivatives |
Feb, 2028
(4 years from now) | |
US7816379 | CUBIST PHARMS LLC | Oxazolidinone derivatives |
Jun, 2028
(5 years from now) | |
US10442829 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(6 years from now) | |
US9624250 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(6 years from now) | |
US8426389 | CUBIST PHARMS LLC | Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Dec, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9988406 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(6 years from now) | |
US10065947 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 20, 2019 |
New Patient Population (NPP) | Jun 19, 2023 |
Generating Antibiotic Incentives Now (GAIN) | Jun 20, 2024 |
NCE-1 date: 2023-06-21
Market Authorisation Date: 20 June, 2014
Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria
Dosage: TABLET;ORAL
18
United States
6
Korea, Republic of
6
China
5
New Zealand
4
Russia
3
Mexico
3
Australia
3
Spain
3
European Union
2
South Africa
2
Hong Kong
2
Singapore
2
Brazil
2
Japan
2
Canada
1
Israel
1
Denmark
1
Austria
1
Lithuania
1
Slovenia
1
Morocco
1
Hungary
1
Philippines
1
Costa Rica
1
Cuba
1
AP
1
Colombia
1
Portugal
1
Cyprus
1
Malaysia
1
Netherlands
1
Peru
1
Poland
1
Dominican Republic
1
Chile
1
Ecuador
1
Luxembourg
1
Ukraine
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic